What’s new
Why it matters
Keep up with the latest headlines on WhatsApp | LinkedIn
The catch
What they’re saying
“This scenario of opaque pricing, restrictive licensing and inadequate global targets will leave far too many people at continued risk of preventable HIV infections,” says Antonio Flores, Senior HIV/TB Advisor at MSF’s Southern Africa Medical Unit. “South Africa cannot afford to repeat past mistakes- it must move quickly to secure lenacapavir for key populations and push for broader access across the region.”
“Generic manufacture of lenacapavir is essential to ensure this breakthrough HIV prevention option is not limited to a privileged few,” says Professor Saiqa Mullick, Director of Implementation Science at Wits RHI, University of the Witwatersrand. “By driving prices down and securing sustainable supply, generics will make six-monthly PrEP a real choice for the millions of people in great need in low- and middle-income countries.”-Health-e News
This article is republished under a Creative Commons Attribution-ShareAlike 4.0 International License.
AllAfrica publishes around 500 reports a day from more than 110 news organizations and over 500 other institutions and individuals, representing a diversity of positions on every topic. We publish news and views ranging from vigorous opponents of governments to government publications and spokespersons. Publishers named above each report are responsible for their own content, which AllAfrica does not have the legal right to edit or correct.
Articles and commentaries that identify allAfrica.com as the publisher are produced or commissioned by AllAfrica. To address comments or complaints, please Contact us.
AllAfrica is a voice of, by and about Africa – aggregating, producing and distributing 500 news and information items daily from over 110 African news organizations and our own reporters to an African and global public. We operate from Cape Town, Dakar, Abuja, Johannesburg, Nairobi and Washington DC.
Get the latest in African news delivered straight to your inbox
By submitting above, you agree to our privacy policy.
Almost finished…
We need to confirm your email address.
To complete the process, please follow the instructions in the email we just sent you.
There was a problem processing your submission. Please try again later.
source
